US · Healthcare

Larimar Therapeutics Inc (LRMR)

Biotechnology

Larimar Therapeutics Inc (LRMR) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-18, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for LRMR

P/E ratio

25.00

Larimar Therapeutics Inc (LRMR) — FAQ

What is LRMR's P/E ratio?

The price-to-earnings (P/E) ratio for Larimar Therapeutics Inc (LRMR) is 25.00 (data as of 2026-05-18).

Does Larimar Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Larimar Therapeutics Inc (LRMR). Check the MyAverix Finance app for the latest dividend data.

What sector is Larimar Therapeutics Inc in?

Larimar Therapeutics Inc (LRMR) is classified in the Healthcare sector (Biotechnology industry).

What exchange is LRMR listed on?

LRMR is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)